Evidence map›Paper›PMID 35494163›Full record

ArticleFree neuropathology2022

Soluble brain homogenates from diverse human and mouse sources preferentially seed diffuse Aβ plaque pathology when injected into newborn mouse hosts.

Brenda D Moore, Yona Levites, Guilian Xu, Hailey Hampton, Munir F Adamo, Cara L Croft, Hunter S Futch, Corey Moran, Susan Fromholt, Christopher Janus and 6 more

Open access · greenAbstract read
In one paragraph

Article in Free neuropathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Brenda D MooreDepartment of Neuroscience, College of Medicine, University of Florida, Gainesville, FL United States.
Yona LevitesDepartment of Neuroscience, College of Medicine, University of Florida, Gainesville, FL United States.
Guilian XuDepartment of Neuroscience, College of Medicine, University of Florida, Gainesville, FL United States.
Hailey HamptonDepartment of Neuroscience, College of Medicine, University of Florida, Gainesville, FL United States.
Munir F AdamoDepartment of Neuroscience, College of Medicine, University of Florida, Gainesville, FL United States.
Cara L CroftDepartment of Neuroscience, College of Medicine, University of Florida, Gainesville, FL United States.
Hunter S FutchDepartment of Neuroscience, College of Medicine, University of Florida, Gainesville, FL United States.
Corey MoranDepartment of Neuroscience, College of Medicine, University of Florida, Gainesville, FL United States.
Susan FromholtDepartment of Neuroscience, College of Medicine, University of Florida, Gainesville, FL United States.
Christopher JanusDepartment of Neuroscience, College of Medicine, University of Florida, Gainesville, FL United States.
Stefan ProkopCenter for Translational Research in Neurodegenerative Disease, College of Medicine, University of Florida, Gainesville, FL United States.
Dennis DicksonDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL United States.
Jada LewisDepartment of Neuroscience, College of Medicine, University of Florida, Gainesville, FL United States.
Benoit I GiassonDepartment of Neuroscience, College of Medicine, University of Florida, Gainesville, FL United States.
Todd E GoldeDepartment of Neuroscience, College of Medicine, University of Florida, Gainesville, FL United States.
David R BorcheltDepartment of Neuroscience, College of Medicine, University of Florida, Gainesville, FL United States.
University of Florida · USMayo Clinic in Florida · US

Funding

Social Determinants of Health, Race/Ethnicity, and White Matter HyperintensitiesP30AG066506 · NIA · UNIVERSITY OF FLORIDA · PI Rosie E Curiel Cid · 2020 to 2026
$25.6M
Utilization of proteomics and lipidomics to identify modifiers of LBDU54NS110435 · NINDS · MAYO CLINIC JACKSONVILLE · PI ROSS, OWEN A · 2019 to 2023
$14.5M
University of Florida - Mt. Sinai Medical Center AD Research CenterP50AG047266 · NIA · UNIVERSITY OF FLORIDA · PI LOEWENSTEIN, DAVID · 2015 to 2019
$7.3M
Is there a form of benign brain amyloidosis in aging?R21AG055113 · NIA · UNIVERSITY OF FLORIDA · PI BORCHELT, DAVID R, LEWIS, JADA M · 2017 to 2018
$419k
Seeded models of AD pathologyR21AG046711 · NIA · UNIVERSITY OF FLORIDA · PI BORCHELT, DAVID R, LEWIS, JADA M · 2014 to 2015
$407k
NIA NIH HHS P30 AG066506NIA NIH HHS P50 AG047266NIA NIH HHS R21 AG046711NIA NIH HHS R21 AG055113NINDS NIH HHS U54 NS110435
6 · The paper itself

Abstract

Background: Seeding of pathology related to Alzheimer's disease (AD) and Lewy body disease (LBD) by tissue homogenates or purified protein aggregates in various model systems has revealed prion-like properties of these disorders. Typically, these homogenates are injected into adult mice stereotaxically. Injection of brain lysates into newborn mice represents an alternative approach of delivering seeds that could direct the evolution of amyloid-β (Aβ) pathology co-mixed with either tau or α-synuclein (αSyn) pathology in susceptible mouse models. Methods: Homogenates of human pre-frontal cortex were injected into the lateral ventricles of newborn (P0) mice expressing a mutant humanized amyloid precursor protein (APP), human P301L tau, human wild type αSyn, or combinations thereof. The homogenates were prepared from AD and AD/LBD cases displaying variable degrees of Aβ pathology and co-existing tau and αSyn deposits. Behavioral assessments of APP transgenic mice injected with AD brain lysates were conducted. For comparison, homogenates of aged APP transgenic mice that preferentially exhibit diffuse or cored deposits were similarly injected into the brains of newborn APP mice. Results: We observed that lysates from the brains with AD (Aβ+, tau+), AD/LBD (Aβ+, tau+, αSyn+), or Pathological Aging (Aβ+, tau-, αSyn-) efficiently seeded diffuse Aβ deposits. Moderate seeding of cerebral amyloid angiopathy (CAA) was also observed. No animal of any genotype developed discernable tau or αSyn pathology. Performance in fear-conditioning cognitive tasks was not significantly altered in APP transgenic animals injected with AD brain lysates compared to nontransgenic controls. Homogenates prepared from aged APP transgenic mice with diffuse Aβ deposits induced similar deposits in APP host mice; whereas homogenates from APP mice with cored deposits induced similar cored deposits, albeit at a lower level. Conclusions: These findings are consistent with the idea that diffuse Aβ pathology, which is a common feature of human AD, AD/LBD, and PA brains, may arise from a distinct strain of misfolded Aβ that is highly transmissible to newborn transgenic APP mice. Seeding of tau or αSyn comorbidities was inefficient in the models we used, indicating that additional methodological refinement will be needed to efficiently seed AD or AD/LBD mixed pathologies by injecting newborn mice.

Indexed as

Alzheimer’s diseaseAmyloid-βLewy body dementiaSeedingTauα-Synuclein

Identifiers

PMID35494163
PMCPMC9053163
OpenAlexW4225313422

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.